

Information Regarding Clinical Trial

Title	A Randomized Phase III Trial To Evaluate The Efficacy and Safety of MK3475(Pembrolizumab) As Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With equal or > 1CM Residual Invasive Cancer
Protocol Number	S1418
Sponsor	SWOG
Investigator	J. Thaddeus Beck, MD 3232 N. North Hills Blvd. Fayetteville, AR 72703
Study Related Phone Numbers	479-587-1700 (24 hours)
Key Points for Study	Patients with TNBC with residual disease after neoadjuvant chemo Followed by surgery